Drug Trial Radar · NCT07220811
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Actual
Start
Dec 15, 2025
Primary completion
Mar 16, 2027
Study completion Dec 21, 2027
Sponsor
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generation anti-IgE monoclonal antibody, in people with food allergy. RPT904 is a long-acting antibody that may allow for dosing every 8 to 12 weeks. Approximately 100 participants between the ages of 12 and 55 with documented allergy to at least one of the following foods: peanut, milk, egg, cashew, or walnut will be enrolled. In Part 1 (24 weeks), participants will be randomly assigned to receive RPT904 every 8 or 12 weeks (plus a loading dose at Week 2), or placebo. In Part 2 (24 weeks), participants who received RPT904 will continue on their assigned dosing schedule, and those who previously received placebo will be re-randomized to receive RPT904 either every 8 or 12 weeks (plus a loading dose at Week 26). All participants will attend study visits approximately every 2-6 weeks throughout both Part 1 and Part 2 to maintain blinding, regardless of treatment group or dosing frequency. The study is being conducted at multiple sites. The primary goal is to assess whether RPT904 helps participants tolerate higher amounts of a food allergen without dose-limiting allergic symptoms during a food challenge. The study will also monitor the safety and side effects of RPT904 over time. Each participant is expected to be in the study for about 68 to 74 weeks, including screening, treatment, and follow-up.
Conditions
- Immune System Diseases
- Ig-E Mediated Food Allergy
Interventions
RPT904Drug
Subcutaneous injection once every 8 weeks
RPT904Drug
Subcutaneous injection once every 12 weeks
PlaceboOther
Subcutaneous injection at the intervening dosing visits
RPT904Drug
Subcutaneous injection once every 8 weeks (Part 2)
RPT904Drug
Subcutaneous injection once every 12 weeks (Part 2)
PlaceboOther
Subcutaneous injection on schedules matching both the Q8W and Q12W arms (Part 1). Subcutaneous injection at the intervening dosing visits (Part 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the ability to consume a food without dose-limiting symptoms during a DBPCFC at the end of Part 1 after treatment with either RPT904 or placeboTime frame: Approximately 24 weeks
Locations
37 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Palo Alto, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Ann Arbor, Michigan
GSK Investigational Site
Minneapolis, Minnesota
GSK Investigational Site
Great Neck, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Chapel Hill, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Westmead, New South Wales, Australia
GSK Investigational Site
South Brisbane, Queensland, Australia
GSK Investigational Site
North Adelaide, South Australia, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Parkville, Victoria, Australia
GSK Investigational Site
Parkville Melbourne, Victoria, Australia
GSK Investigational Site
Murdoch, Western Australia, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Burlington, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.